You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Carcinoma, Non-Small-Cell Lung

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy Trial in Wuhan (CTV omitted or delineated)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • CTV omitted or delineated
  • Wuhan, Hubei, China
    Hubei Cancer Hospital
Sep 1, 2023

NSCLC Trial (ABBV-400)

Available
  • Non-Small Cell Lung Cancer
  • (no location specified)
Aug 1, 2023

Identify Resected Non-small-cell Lung Cancer With High Risk of

Recruiting
  • Non-small Cell Lung Cancer Stage IIIA
  • Resected non small cell lung cancer
  • Toulouse, France
    Julien MAZIERES
Feb 8, 2023

Advanced Non-small-cell Lung Cancer Trial in Shanghai (AK112, AK104, caboplatin)

Not yet recruiting
  • Advanced Non-small-cell Lung Cancer
  • Shanghai, China
    Shanghai Pulmonary Hospital
Jun 6, 2023

Advanced NSCLC Trial in Jinan (almonertinib)

Recruiting
  • Advanced Non-small Cell Lung Cancer
  • Jinan, Shandong, China
    Degan Lu
Sep 12, 2023

Non Small Cell Lung Cancer, Propranolol Trial (Propranolol HCl, Sintilimab, Chemotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Propranolol
  • Propranolol hydrochloride
  • +2 more
  • (no location specified)
Jul 31, 2023

NSCLC Trial (TAS3351 oral administration)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • TAS3351 oral administration
  • (no location specified)
Mar 8, 2023

NSCLC Trial in Houston (Amivantamab, Tepotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma

Active, not recruiting
  • Non Small Cell Lung Cancer
  • Immune signature in serum associated to the metabolic signature
  • Meta-genomic signature of intestinal flora
  • La Tronche, Isère, France
    University Hospital, Grenoble
Jan 6, 2023

Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)

Recruiting
  • Nonsmall Cell Lung Cancer
  • HS-10365 capsules
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Nov 22, 2023

NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • (no location specified)
Mar 27, 2023

Omitting Clinical Target Volume in Radical Treatment of

Not yet recruiting
  • Immunotherapy
  • +3 more
  • IMRT+adjuvant immunotherapy
  • (no location specified)
Jun 9, 2023

Untreated Advanced NSCLC Trial in Fuzhou (Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and

Recruiting
  • Untreated Advanced Non-small Cell Lung Cancer
  • Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
  • Fuzhou, Fujian, China
    Fujian Cancer Hospital
Nov 13, 2023

NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)

Not yet recruiting
  • Non-Small Cell Lung Cancer(NSCLC)
  • WX-0593 Tablets
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Mar 1, 2023

DevelopingShared Decision Making Tool for Surgically Removed

Recruiting
  • Lung Non-Small Cell Carcinoma
  • Discussion
  • Questionnaire Administration
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

NSCLC Trial (Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Tislelizumab IV
  • +2 more
  • (no location specified)
Oct 25, 2023

Unresectable Lung Non-Small Cell Carcinoma Trial (serplulimab plus chemo as conversion treatment)

Not yet recruiting
  • Unresectable Lung Non-Small Cell Carcinoma
  • serplulimab plus chemotherapy as conversion treatment
  • (no location specified)
Apr 27, 2023

EGFR Mutant Advanced NSCLC Trial (BBT-207)

Not yet recruiting
  • EGFR Mutant Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jun 16, 2023

NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)

Not yet recruiting
  • NSCLC
  • Non-small Cell Lung Cancer
  • Apatinib + Fluzoparib
  • Apatinib + Fluzoparib + Adebrelimab
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 27, 2023

NSCLC Trial (Ivonescimab Injection, Pembrolizumab Injection)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Ivonescimab Injection
  • Pembrolizumab Injection
  • (no location specified)
Jun 9, 2023

NSCLC, Carcinoma, Small Cell Lung, Carcinoma, Thymic Trial run by the National Cancer Institute (NCI) (AZD6244, MK-2206,

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022

NSCLC Trial in Guangzhou (PLB1001)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Aug 15, 2023

NSCLC, Non-Small Cell Lung Carcinoma, NSCLC Trial run by the National Cancer Institute (NCI) (biological, drug, device)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Montanide (Registered Trademark) ISA-51 VG Adjuvant
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Non Small Cell Lung Cancer Trial (TGRX-326, Crizotinib)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • (no location specified)
Oct 8, 2023

Advanced Non Small Cell Lung Cancer Trial run by the National Cancer Institute (NCI) (aerosolized aztreonam, aerosolized

Not yet recruiting
  • Advanced Non Small Cell Lung Cancer
  • aerosolized aztreonam
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Mar 28, 2023